Add like
Add dislike
Add to saved papers

Treatment Options for Anti-N-methyl-D-aspartate Receptor Encephalitis.

Anti-NMDAR encephalitis is an autoimmune limbic disorder with an unknown cause, which affects mostly young women. Behavioral changes, seizures, orofacial muscle contractions, and memory impairment are usually observed. The variability of the symptoms depends on which part of the brain is inflamed. Treatment options aim to reduce serious neurological damage. Early diagnosis combined with the proper treatment favorably impacts the outcome. In our facility, weekly induction therapy is started pending an investigation into an associated ovarian or other tumor. Two case studies are discussed with favorable outcomes. The first is an outstanding case study with refractory status epilepticus caused by anti-NMDA receptors with benign teratoma which improved following combination therapy with rituximab and cyclophosphamide. There was no response to benzodiazepines and to an abundant number of antiepileptic drugs. Brain magnetic resonance imaging clearly indicated severe brain atrophy in the first case. Serial EEG monitoring showed a multitude of abnormalities. Delta brush activity was interictal and distinctive of anti-NMDAR encephalitis.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app